Build Your Comparison

Side-by-side financial analysis
PMN logo
PMN
PRTA logo
PRTA
ARVN logo
ARVN
KO logo
KO
Try popular comparisons:

Stock Comparison

PMN vs PRTA vs ARVN vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PMN
ProMIS Neurosciences, Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$68M
5Y Perf.-95.7%
PRTA
Prothena Corporation plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$432M
5Y Perf.-21.1%
ARVN
Arvinas, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$489M
5Y Perf.-77.4%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

PMN vs PRTA vs ARVN vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PMN logoPMN
PRTA logoPRTA
ARVN logoARVN
KO logoKO
IndustryBiotechnologyBiotechnologyBiotechnologyBeverages - Non-Alcoholic
Market Cap$68M$432M$489M$355.61B
Revenue (TTM)$0.00$58M$89M$49.28B
Net Income (TTM)$-41M$-151M$-221M$13.70B
Gross Margin46.8%97.4%61.7%
Operating Margin-217.9%-279.3%29.3%
Forward P/E176.7x25.3x
Total Debt$0.00$14M$9M$45.49B
Cash & Equiv.$6M$308M$143M$10.27B

PMN vs PRTA vs ARVN vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PMN
PRTA
ARVN
KO
StockJun 20Jun 26Return
ProMIS Neuroscience… (PMN)1004.3-95.7%
Prothena Corporatio… (PRTA)10078.9-21.1%
Arvinas, Inc. (ARVN)10022.6-77.4%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: PMN vs PRTA vs ARVN vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. ProMIS Neurosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility. PRTA also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
PMN
ProMIS Neurosciences, Inc.
The Income Pick

PMN is the #2 pick in this set and the best alternative if income & stability is your priority.

  • beta 1.11
  • Beta 1.11 vs PRTA's 1.50
Best for: income & stability
PRTA
Prothena Corporation plc
The Momentum Pick

PRTA is the clearest fit if your priority is momentum.

  • +62.7% vs PMN's -20.4%
Best for: momentum
ARVN
Arvinas, Inc.
The Defensive Pick

ARVN is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 1.14, Low D/E 2.1%, current ratio 4.92x
  • Beta 1.14, current ratio 4.92x
Best for: sleep-well-at-night and defensive
KO
The Coca-Cola Company
The Growth Play

KO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
  • 121.1% 10Y total return vs ARVN's -52.8%
  • 1.9% revenue growth vs PRTA's -92.8%
  • Better valuation composite
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthKO logoKO1.9% revenue growth vs PRTA's -92.8%
ValueKO logoKOBetter valuation composite
Quality / MarginsKO logoKO27.8% margin vs PRTA's -260.9%
Stability / SafetyPMN logoPMNBeta 1.11 vs PRTA's 1.50
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)PRTA logoPRTA+62.7% vs PMN's -20.4%
Efficiency (ROA)KO logoKO13.1% ROA vs PMN's -151.0%

PMN vs PRTA vs ARVN vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PMNProMIS Neurosciences, Inc.

Segment breakdown not available.

PRTAProthena Corporation plc
FY 2025
Collaboration
99.5%$10M
License
0.5%$50,000
ARVNArvinas, Inc.
FY 2025
License
100.0%$130M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

PMN vs PRTA vs ARVN vs KO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGPRTA

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

KO and PMN operate at a comparable scale, with $49.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to PRTA's -2.6%. On growth, PRTA holds the edge at +17.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$0$58M$89M$49.3B
EBITDAEarnings before interest/tax-$41M-$124M-$245M$15.5B
Net IncomeAfter-tax profit-$41M-$151M-$221M$13.7B
Free Cash FlowCash after capex-$35M-$81M-$257M$12.6B
Gross MarginGross profit ÷ Revenue+46.8%+97.4%+61.7%
Operating MarginEBIT ÷ Revenue-2.2%-2.8%+29.3%
Net MarginNet income ÷ Revenue-2.6%-2.5%+27.8%
FCF MarginFCF ÷ Revenue-140.6%-2.9%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+17.1%-91.7%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+76.0%+153.6%-178.9%+18.2%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ARVN leads this category, winning 3 of 4 comparable metrics.
MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
Market CapShares × price$68M$432M$489M$355.6B
Enterprise ValueMkt cap + debt − cash$61M$138M$355M$390.8B
Trailing P/EPrice ÷ TTM EPS-0.46x-1.82x-5.92x27.18x
Forward P/EPrice ÷ next-FY EPS est.176.66x25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue44.60x1.86x7.42x
Price / BookPrice ÷ Book value/share1.58x1.13x10.40x
Price / FCFMarket cap ÷ FCF67.15x
ARVN leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 5 of 8 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-2 for PMN. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs PMN's 0/9, reflecting strong financial health.

MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-2.4%-49.9%-44.4%+41.1%
ROA (TTM)Return on assets-151.0%-42.3%-28.4%+13.1%
ROICReturn on invested capital-21.0%-22.4%+15.8%
ROCEReturn on capital employed-5.2%-47.0%-16.0%+17.3%
Piotroski ScoreFundamental quality 0–90147
Debt / EquityFinancial leverage0.05x0.02x1.33x
Net DebtTotal debt minus cash-$6M-$294M-$134M$35.2B
Cash & Equiv.Liquid assets$6M$308M$143M$10.3B
Total DebtShort + long-term debt$0$14M$9M$45.5B
Interest CoverageEBIT ÷ Interest expense10.70x
KO leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $363 for PMN. Over the past 12 months, PRTA leads with a +62.7% total return vs PMN's -20.4%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs PMN's -56.0% — a key indicator of consistent wealth creation.

MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date+45.0%-10.3%-33.9%+20.3%
1-Year ReturnPast 12 months-20.4%+62.7%+0.1%+17.2%
3-Year ReturnCumulative with dividends-91.5%-88.7%-73.7%+47.0%
5-Year ReturnCumulative with dividends-96.4%-82.7%-91.0%+65.6%
10-Year ReturnCumulative with dividends-91.4%-82.0%-52.8%+121.1%
CAGR (3Y)Annualised 3-year return-56.0%-51.7%-35.9%+13.7%
KO leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than PRTA's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs PMN's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.11x1.50x1.14x-0.20x
52-Week HighHighest price in past year$39.75$11.80$14.51$84.04
52-Week LowLowest price in past year$6.27$4.95$6.06$65.35
% of 52W HighCurrent price vs 52-week peak+26.0%+69.9%+52.2%+98.3%
RSI (14)Momentum oscillator 0–10051.835.624.160.6
Avg Volume (50D)Average daily shares traded34K447K794K12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: PMN as "Buy", PRTA as "Buy", ARVN as "Buy", KO as "Buy". Consensus price targets imply 130.3% upside for PRTA (target: $19) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricPMN logoPMNProMIS Neuroscien…PRTA logoPRTAProthena Corporat…ARVN logoARVNArvinas, Inc.KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$18.00$19.00$14.75$86.13
# AnalystsCovering analysts2282648
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises56
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+18.8%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

KO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARVN leads in 1 (Valuation Metrics).

Best OverallThe Coca-Cola Company (KO)Leads 4 of 6 categories
Loading custom metrics...

PMN vs PRTA vs ARVN vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PMN or PRTA or ARVN or KO a better buy right now?

For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.

9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PMN or PRTA or ARVN or KO?

On forward P/E, The Coca-Cola Company is actually cheaper at 25.

3x.

03

Which is the better long-term investment — PMN or PRTA or ARVN or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: KO returned +121. 1% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PMN or PRTA or ARVN or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Prothena Corporation plc's 1. 50β — meaning PRTA is approximately -850% more volatile than KO relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — PMN or PRTA or ARVN or KO?

By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.

9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PMN or PRTA or ARVN or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PMN or PRTA or ARVN or KO more undervalued right now?

On forward earnings alone, The Coca-Cola Company (KO) trades at 25.

3x forward P/E versus 176. 7x for Prothena Corporation plc — 151. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.

08

Which pays a better dividend — PMN or PRTA or ARVN or KO?

In this comparison, KO (2.

5% yield) pays a dividend. PMN, PRTA, ARVN do not pay a meaningful dividend and should not be held primarily for income.

09

Is PMN or PRTA or ARVN or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PMN and PRTA and ARVN and KO?

These companies operate in different sectors (PMN (Healthcare) and PRTA (Healthcare) and ARVN (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while PMN, PRTA, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.